Growth Metrics

Vanda Pharmaceuticals (VNDA) Deferred Taxes (2019 - 2025)

Vanda Pharmaceuticals' Deferred Taxes history spans 8 years, with the latest figure at $103.2 million for Q4 2025.

  • On a quarterly basis, Deferred Taxes rose 5491.12% to $103.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $81.4 million, a 1356.45% increase, with the full-year FY2025 number at $81.4 million, up 1356.45% from a year prior.
  • Deferred Taxes hit $103.2 million in Q4 2025 for Vanda Pharmaceuticals, up from -$6.0 million in the prior quarter.
  • Over the last five years, Deferred Taxes for VNDA hit a ceiling of $103.2 million in Q4 2025 and a floor of -$8.0 million in Q2 2025.
  • Historically, Deferred Taxes has averaged $4.1 million across 5 years, with a median of $85500.0 in 2022.
  • The widest YoY moves for Deferred Taxes: up 5491.12% in 2025, down 3069.51% in 2025.
  • Tracing VNDA's Deferred Taxes over 5 years: stood at $1.3 million in 2021, then plummeted by 68.24% to $417000.0 in 2022, then plummeted by 1894.72% to -$7.5 million in 2023, then skyrocketed by 74.43% to -$1.9 million in 2024, then soared by 5491.12% to $103.2 million in 2025.
  • Business Quant data shows Deferred Taxes for VNDA at $103.2 million in Q4 2025, -$6.0 million in Q3 2025, and -$8.0 million in Q2 2025.